Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.
Separately, Weiss Ratings raised shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.25.
Read Our Latest Stock Report on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. The company had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $6.30 million. Analysts predict that Arcturus Therapeutics will post -3.99 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ARCT. AQR Capital Management LLC bought a new stake in shares of Arcturus Therapeutics in the 1st quarter worth about $128,000. Millennium Management LLC acquired a new stake in shares of Arcturus Therapeutics during the 1st quarter worth about $4,892,000. Goldman Sachs Group Inc. lifted its holdings in Arcturus Therapeutics by 9.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after purchasing an additional 42,636 shares during the last quarter. Acadian Asset Management LLC bought a new position in Arcturus Therapeutics during the 1st quarter valued at about $701,000. Finally, Strs Ohio acquired a new position in Arcturus Therapeutics in the first quarter valued at about $89,000. 94.54% of the stock is owned by institutional investors.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.
The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.
Further Reading
- Five stocks we like better than Arcturus Therapeutics
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
